Introduction: Other polymorphisms including A131G, G132C, C143G, G145T, G176A, T178G and C335T generate the amino acid changes R10G/I, Q14H/D, D25E/N, I27R and H78Y, respectively.
Discussion: According to the HPV variants found in this study, the amino acid substitutions circulating in Southern Mexico are: Q3E, R10G, Q14H, D25N, I27L, I27R PMID: 24150786
2014
Journal of medical virology
Abstract: A rare variation, EUR E6-R10G, was found to shorten the half-life of p53 more efficiently than the other variations.
Analysis of mutations in the E6 oncogene of human papillomavirus 16 in cervical cancer isolates from Moroccan women.
Result: The other non-synonymous variants were R10I (G132T), R10G (A131G), D64E (T295G), Q14H (G145T) and A61G (C285G) and were seen in 23.3%, 6.8%, 6.8%, 1.9% and 1% of cases respectively.
Discussion: Additionally, E6 variants R10G/L83V and Q14H/H78Y/L83V which are frequently detected in our study, were more prone to undergo cell-detachment-induced apoptosis than E6 prototype in a model of human normal i
Genetic variations of E6 and long control region of human papillomavirus type 16 from patients with cervical lesion in Liaoning, China.
Result: Two nonsynonymous variations of A131G (R10G) a
Discussion: In our study, the alone L83V variation in HPV16 E6 was not associated with an increased risk of CIN2,3, but together with R10G, the nonsynonymous variations R10G/L83V were associated significantly with an increased risk for developing CIN2,3.
Discussion: It has been demonstrated that amino acid changes of R10G/L83V can alter the ability of E6 to bind and degrade p53, induce antiapoptotic signals or alter their binding affinity with host HLA.
Human papillomavirus (HPV) 16 E6 variants in tonsillar cancer in comparison to those in cervical cancer in Stockholm, Sweden.
Result: When all the 108 samples were summarized 19% had R10G and 40% the L83V mutation.
Discussion: E6 with both the R10G and L83 alteration, which 9/12
Discussion: Further studies are needed to investigate if the R10G variant may be more common in oral as compared to cervical samples.
Discussion: However, while E6 with R10G has a decreased binding to E6BP (E6-binding protein) and reduced ability to induce Bax degradation, E6 with L83V E6 has an increased binding to E6BP and retained ability to induce Bax degradation compared to prototype HPV16 E6.
Whole genome sequencing and evolutionary analysis of human papillomavirus type 16 in central China.
Abstract: Bayesian analysis identified several important amino acid positions that may be driving adaptive selection in the HPV 16 population, including R10G, D25E, L83V, and E113D in the E6 gene.
Rare human papillomavirus 16 E6 variants reveal significant oncogenic potential.
Result: those with low prevalence in cervical carcinomas of previously studied European populations, including variant R8Q, R10G, and R48W.
Discussion: R10G and R48W induced hyperplastic proliferation similar to that induced by the high prevalence type L83V, whereas the R8Q cultures had a unique phenotype, characterized by lack of stratification.
Discussion: Previous studies with site directed mutants demonstrated that other amino acid changes in the same positions as those of R8Q and R10G, did impair the ability of E6 to induce p53 degradation.
Human papillomavirus 16 E6 variants differ in their dysregulation of human keratinocyte differentiation and apoptosis.
Abstract: In addition, E6 variant NIKS expressing R10G/L83V and Q14H/H78Y/L83V were more prone to undergo cell-detachment-induced apoptosis (anoikis) than NIKS expressing E6 prototype.
Discussion: Indeed, CaSki cells (R10G/L83V) more than SiHa cells (L83V) have been reported to undergo apoptosis when deprived of cell anchorage.
Discussion: Nevertheless both Q14H/H78Y/L83V and R10G/L83V demonstrated significantly higher levels of late apoptosis than
Absence of antibody against human papillomavirus type 16 E6 and E7 in patients with cervical cancer is independent of sequence variations.
PMID: 10783118
2000
The Journal of infectious diseases
Abstract: All E6 antigens (the prototype and the variants 350G?L83V, 131G?R10G/350G?L83V, 335T?H78Y/350G?L83V, 345G?Y81C/350G?L83V, and African 2 ?Af2) showed cross-reactivity by RIPA.
HPV mutation literature information.
PMID: 
2015
Virology journal
Browser Board
Co-occurred Entities
Filtrator
ViMRT